<DOC>
	<DOCNO>NCT00782821</DOCNO>
	<brief_summary>The purpose research study find effect add B lymphocyte modulate agent patient risk rejection receive anti-rejection ( immunosuppressive ) regimen Thymoglobulin® induction Prograf® , Cellcept® corticosteroid therapy .</brief_summary>
	<brief_title>Randomized Trial Induction Therapies High Immunological Risk Kidney Transplant Recipients</brief_title>
	<detailed_description>Optimal induction regimens patient high risk antibody and/or cell-mediated rejection establish . This pilot , prospective , randomize study evaluate addition B cell/plasma cell-targeting agent T cell-based induction rabbit antithymocyte globulin ( rATG ) high immunologic risk renal transplant recipient . Patients randomized induction rATG , rATGþrituximab , rATGþbortezomib rATGþrituximabþbortezomib .</detailed_description>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Inclusion Criteria Each patient must meet follow inclusion criterion enrol study : Voluntary write informed consent performance studyrelated procedure part normal medical care , understand consent may withdraw subject time without prejudice future medical care . Patient 18 65 year age , inclusive . Patient consider high risk acute rejection base one follow : Patient current Cytotoxic PRA≥ 20 % peak Cytotoxic PRA ≥50 % Patient T Bcell positive crossmatch ( flow cytometry ) confirm donorspecific antibody solidphase assay . Historical positive serologic cytotoxic crossmatch DSA donor Prior allograft loss history one acute rejection episode . Female subject either postmenopausal least 1 year prior initiation study treatment , surgically sterilize , childbearing potential , agree practice 2 effective method contraception time sign informed consent form 30 day last dose bortezomib , agree completely abstain heterosexual intercourse . Women childbearing potential must negative serum pregnancy test within last 48 hour prior receive study medication . Male subject , even surgically sterilize ( i.e . status postvasectomy ) must agree 1 following : practice effective barrier contraception entire study treatment period minimum 30 day last dose study drug , completely abstain heterosexual intercourse . Patient must know contraindication treatment bortezomib , rituximab , thymoglobulin . Exclusion Criteria Patients previously receive receive organ transplant kidney . Patient lose previous allograft due recurrence disease Patient receive HLA identical living relate kidney transplant History severe allergic anaphylactic reaction humanize murine monoclonal polyclonal antibody Patients absolute neutrophil count &lt; 1,000/mm3 platelet count &lt; 100,000/mm3within 30 day consent . Patient Grade 2 peripheral neuropathy CTCAE criterion within 14 day enrollment . Myocardial infarction within 6 month prior enrollment New York Heart Association ( NYHA ) Class III IV heart failure ( see section 9.3 ) , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality . Prior study entry , abnormality ECG perform within 30 day consent document investigator patient 's transplant nephrologist medically relevant . Patients antiHIVpositive , HBsAgpositive AntiHCV positive testing perform within one year consent . Diagnosed treated malignancy within 3 year enrollment , exception complete resection basal cell carcinoma squamous cell carcinoma skin , situ malignancy , lowrisk prostate cancer curative therapy . Patients current recent severe systemic infection within 2 week prior initiation study treatment . Receipt live vaccine within 4 week prior initiation study treatment . Use investigational drug within 30 day 5 halflives prior initiation study treatment , whichever long Evidence severe liver disease medical history physical exam abnormal liver profile ( aspartate aminotransferase [ AST ] , alanine aminotransferase [ ALT ] total bilirubin &gt; 1.5 time upper limit normal [ ULN ] ) test perform within 30 day consent . Pregnant nursing ( lactate ) woman woman might become pregnant study . Female subject pregnant breastfeeding . Confirmation subject pregnant must establish negative serum human chorionic gonadotropin pregnancy test result within last 48 hour prior receive study medication . Pregnancy test require postmenopausal surgically sterilize woman . EBV serologic mismatch ( i.e . EBV+ donor transplant EBV recipient ) CMV serologic mismatch ( i.e . CMV+ donor transplant CMV recipient )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Kidney</keyword>
	<keyword>Renal</keyword>
	<keyword>Rejection</keyword>
	<keyword>High risk</keyword>
	<keyword>Induction</keyword>
	<keyword>Immunology</keyword>
	<keyword>Transplantation</keyword>
	<keyword>B Cell</keyword>
	<keyword>Allograft</keyword>
	<keyword>Desensitization</keyword>
</DOC>